Features of vulnerable plaques and clinical outcome of UA/NSTEMI: Relationship with matrix metalloproteinase functional polymorphisms

Braunwald, 2002, J Am Coll Cardiol, 40, 1366, 10.1016/S0735-1097(02)02336-7 Virmani, 2003, Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque, J Interv Cardiol, 16, 267, 10.1034/j.1600-0854.2003.8042.x Ding, 2008, The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke, Am J Med Sci, 336, 27, 10.1097/MAJ.0b013e31815b60a1 Giansante, 2007, In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers, J Cardiovasc Med (Hagerstown), 8, 602, 10.2459/JCM.0b013e32802e6c28 Galis, 1994, Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques, J Clin Invest, 94, 2493, 10.1172/JCI117619 Rutter, 1998, A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription, Cancer Res, 58, 5321 Ye, 1995, Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis, Br Heart J, 73, 209, 10.1136/hrt.73.3.209 Shimajiri, 1999, Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene, FEBS Lett, 455, 70, 10.1016/S0014-5793(99)00863-7 Cao, 2009, Effect of matrix metalloproteinase-1 promoter genotype on interleukin-1beta-induced matrix metalloproteinase-1 production in human periodontal ligament cells, J Periodontal Res Fornoni, 2002, Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice, J Am Soc Nephrol, 13, 2068, 10.1097/01.ASN.0000022421.86757.8D Fukuda, 2006, Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris, Am J Cardiol, 97, 175, 10.1016/j.amjcard.2005.08.020 Zhu, 2006, Allele-specific MMP-3 transcription under in vivo conditions, Biochem Biophys Res Commun, 348, 1150, 10.1016/j.bbrc.2006.07.174 Abilleira, 2006, The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis, J Med Genet, 43, 897, 10.1136/jmg.2006.040808 Nojiri, 2003, Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese, Int J Cardiol, 92, 181, 10.1016/S0167-5273(03)00100-1 Pearce, 2005, Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction, Circ Res, 97, 1070, 10.1161/01.RES.0000189302.03303.11 Ghaderian, 2010, Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction, Coron Artery Dis, 21, 330, 10.1097/MCA.0b013e32833ce065 Yoon, 1999, Genetic analysis of MMP3 MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms, Biochem Biophys Res Commun, 265, 563, 10.1006/bbrc.1999.1721 Fiotti, 2006, MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis, Arterioscler Thromb Vasc Biol, 26, 1330, 10.1161/01.ATV.0000219233.31702.c9 Nikkari, 1995, Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis, Circulation, 92, 1393, 10.1161/01.CIR.92.6.1393 Lemaitre, 2001, ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis, J Clin Invest, 107, 1227, 10.1172/JCI9626 Ghaderian, 2010, Matrix metalloproteinase: investigation from gene to protein as effective factor in myocardial infarction, J Thromb Thrombolysis, 10.1007/s11239-010-0465-5 Oettgen, 2006, Regulation of vascular inflammation and remodeling by ETS factors, Circ Res, 99, 1159, 10.1161/01.RES.0000251056.85990.db Nelson, 2006, Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through Ets and AP-1 promoter motifs, J Biol Chem, 281, 14100, 10.1074/jbc.M601820200 Miwa, 2005, Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model, Gene Ther, 12, 1109, 10.1038/sj.gt.3302496 Newby, 2005, Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability, Circ Res, 97, 958, 10.1161/01.RES.0000193565.23357.c0 Limb, 2005, Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis, Am J Pathol, 166, 1555, 10.1016/S0002-9440(10)62371-1 Johnson, 2005, Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries, Proc Natl Acad Sci USA, 102, 15575, 10.1073/pnas.0506201102 Zhang, 2001, Polymorphisms in matrix metalloproteinase-1, -3 -9, and -12 genes in relation to subarachnoid hemorrhage, Stroke, 32, 2198, 10.1161/hs0901.095382 Fiotti, 2008, Metalloproteinases-2 -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI, Int J Cardiol, 127, 350, 10.1016/j.ijcard.2007.05.011 Ducharme, 2000, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction, J Clin Invest, 106, 55, 10.1172/JCI8768 Tamura, 2004, Proapoptotic effect of proteolytic activation of matrix metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus pyrogenic exotoxin B), Infect Immun, 72, 4836, 10.1128/IAI.72.8.4836-4847.2004 Gautier, 2009, Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage, Circulation, 119, 1795, 10.1161/CIRCULATIONAHA.108.806158